Olumiant (baricitinib) / Eli Lilly, Incyte  >>  Phase 3
Welcome,         Profile    Billing    Logout  

63 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
RA-BEACON, NCT01721044 / 2012-002323-15: A Moderate to Severe Rheumatoid Arthritis Study

Checkmark BMJD 2016: RA-BEACON
Nov 2016 - Nov 2016: BMJD 2016: RA-BEACON
Checkmark RA-BEACON
Nov 2016 - Nov 2016:  RA-BEACON
Checkmark ARA 2016: RA-BUILD; RA-BEACON
More
Completed
3
527
Europe, Canada, Japan, US, RoW
Placebo, Baricitinib, LY 3009104, INCB 028050, cDMARD
Eli Lilly and Company, Eli Lilly and Company, , Lilly S.A.
Rheumatoid Arthritis
06/14
09/14
RA-BUILD, NCT01721057 / 2012-002339-27: A Study in Moderate to Severe Rheumatoid Arthritis Participants

Checkmark BMJD 2016: RA-BUILD
Nov 2016 - Nov 2016: BMJD 2016: RA-BUILD
Checkmark ARA 2016: RA-BUILD; RA-BEACON
May 2016 - May 2016: ARA 2016: RA-BUILD; RA-BEACON
Checkmark BSR 2016: RA-BUILD
More
Completed
3
684
Europe, Canada, Japan, US, RoW
Placebo, Baricitinib, LY 3009104, INCB 028050, cDMARD
Eli Lilly and Company, , Eli Lilly and Company, Lilly
Rheumatoid Arthritis
09/14
12/14
RA-BEGIN, NCT01711359 / 2012-002324-32: A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Checkmark EULAR 2016
Jun 2016 - Jun 2016: EULAR 2016
Checkmark RA-BEGIN in RA at ACR 2015
Nov 2015 - Nov 2015: RA-BEGIN in RA at ACR 2015
Checkmark RA-BEGIN
More
Completed
3
588
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Eli Lilly and Company
Rheumatoid Arthritis
02/15
08/15
RA-BEAM, NCT01710358 / 2012-002322-73: A Study in Moderate to Severe Rheumatoid Arthritis

Checkmark ACR/ARHP 2017: RA BEAM
Nov 2017 - Nov 2017: ACR/ARHP 2017: RA BEAM
Checkmark RA-BEAM
Feb 2017 - Feb 2017: RA-BEAM
Checkmark EULAR 2016: RA-BEAM
More
Completed
3
1307
Europe, Canada, Japan, US, RoW
Adalimumab, Baricitinib, LY 3009104, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Eli Lilly and Company, , Eli Lilly and Company, n/a, Lilly S.A.
Rheumatoid Arthritis
03/15
09/15
2012-002323-15: A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis

 
3
40
Europe, RoW
baricitinib, LY3009104,
ELI LILLY AND COMPANY, Eli Lilly and Company, Lilly S.A., Eli Lilly and Company, , Lilly S.A.
Moderately to severely active rheumatoid arthritis
 
09/14
2012-002339-27: A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis

 
3
25
Europe
baricitinib, LY3009104,
Eli Lilly and Company, ELI LILLY AND COMPANY, Lilly S.A., , Eli Lilly and Company, Lilly
Moderately to severely active rheumatoid arthritis
 
12/14
2012-002322-73: A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis.

 
3
40
Europe
baricitinib, LY3009104, Humira, Humira
Eli Lilly and Company, Lilly S.A., , Eli Lilly and Company, n/a, Lilly S.A.
Moderately to severely active rheumatoid arthritis
 
09/15
NCT02265705: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

Completed
3
290
RoW
Baricitinib, LY3009104, INCB 028050, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
05/17
05/17
BREEZE-AD1, NCT03334396 / 2017-000870-12: A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Checkmark BREEZE-AD1 trial
Feb 2019 - Feb 2019: BREEZE-AD1 trial
Completed
3
660
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
12/18
08/19
BREEZE-AD2, NCT03334422 / 2017-000871-10: Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Checkmark Safety and efficacy data from BREEZE-AD2 trial in moderate to severe atopic dermatitis
Feb 2019 - Feb 2019: Safety and efficacy data from BREEZE-AD2 trial in moderate to severe atopic dermatitis
Completed
3
615
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
12/18
12/18
2016-004675-52: A Study of Baricitinib (LY3009104) in Participants With Active Psoriatic Arthritis

Ongoing
3
622
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Eli Lilly and Company, Lilly S.A., ELI LILLY & COMPANY, LILLY CORPORATE CENTER, Eli Lilly and Company
Active Psoriatic Arthritis, Psoriatic Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
BREEZE-AD7, NCT03733301 / 2018-001726-26: A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

Checkmark Detailed 16-week data from BREEZE-AD7 trial
Oct 2019 - Oct 2019: Detailed 16-week data from BREEZE-AD7 trial
Checkmark Efficacy and safety data in adults from BREEZE-AD7 trial
Aug 2019 - Aug 2019: Efficacy and safety data in adults from BREEZE-AD7 trial
Completed
3
329
Europe, Japan, RoW
Baricitinib, LY3009104, Topical corticosteroid, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
07/19
08/19
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

Checkmark Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Jan 2020 - Jan 2020:  Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Completed
3
463
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
11/19
04/23
BREEZE-AD5, NCT03435081: A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Checkmark Efficacy and safety data from BREEZE-AD5 study in adult patients with moderate to severe atopic dermatitis
Jan 2020 - Jan 2020: Efficacy and safety data from BREEZE-AD5 study in adult patients with moderate to severe atopic dermatitis
Completed
3
440
Canada, US
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
12/19
08/21
2020-001052-18: A Multicentre, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults

Ongoing
3
800
Europe, RoW
Remdesivir, Not applicable, Infusion, Olumiant
Regents of the University of Minnesota, National Institute of Health, University of Minnesota, University of Minnesota, USA
COVID-19 (Coronavirus RNA), COVID-19 (A respiratory disease caused by a novel coronavirus), Health Care [N] - Environment and Public Health [N06]
 
 
NCT04401579: Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

Checkmark Additional efficacy and safety data from ACTT-2 trial in combination with Olumiant for COVID-19
Oct 2020 - Oct 2020: Additional efficacy and safety data from ACTT-2 trial in combination with Olumiant for COVID-19
Checkmark From ACTT-2 trial in combination with Olumiant for COVID-19
Sep 2020 - Sep 2020: From ACTT-2 trial in combination with Olumiant for COVID-19
Completed
3
1033
Europe, Japan, US, RoW
Placebo, Remdesivir, Baricitinib
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/20
07/20
BREEZE-AD3, NCT03334435 / 2017-000873-35: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Completed
3
1645
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
09/20
07/23
RA-BEYOND, NCT01885078 / 2012-003686-17: An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

Checkmark EULAR 2016
Jun 2016 - Jun 2016: EULAR 2016
Checkmark EULAR 2016
Jun 2016 - Jun 2016: EULAR 2016
Checkmark RA-BEYOND
More
Completed
3
2877
Europe, Canada, Japan, US, RoW
Baricitinib, LY 3009104, INCB 028050, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
11/20
11/20
BRAVE-AA2, NCT03899259: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Mar 2021 - Mar 2021: Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Active, not recruiting
3
546
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
01/21
12/24
COV-BARRIER, NCT04421027 / 2020-001517-21: A Study of Baricitinib (LY3009104) in Participants With COVID-19

Checkmark Efficacy and safety data from additional cohort of COV-BARRIER trial
Aug 2021 - Aug 2021: Efficacy and safety data from additional cohort of COV-BARRIER trial
Checkmark Efficacy and safety data from COV-BARRIER trial
Apr 2021 - Apr 2021: Efficacy and safety data from COV-BARRIER trial
Completed
3
1525
Europe, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
COVID-19
02/21
06/21
NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Recruiting
3
150
RoW
Remdesivir, Ninavir, Baricitinib, Tocilizumab
M Abdur Rahim Medical College and Hospital, First affiliated Hospital Xi'an Jiaoting University
Covid19, Covid-19 ARDS
02/21
03/21
2020-004987-24: Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs

Not yet recruiting
3
62
Europe
Baricitinib, Tablet, OLUMIANT 4mg
Assistance Publique-Hopitaux de Paris, ministere de la santé
Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat analysis. Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs. Essai contrôlé randomisé en double aveugle multicentrique avec 2 groupes parallèles. Il s'agit d'un essai en add-on en intention de traiter, Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs, Body processes [G] - Immune system processes [G12]
 
 
2020-004345-37: Combination of baricitinib and adalimumab vs. baricitinib alone in patients with rheumatoid arthritis Efficacité et tolerance de la combinaison baricitinib /adalimumab vs. baricitinib seul dans le traitement de la polyarthrite rhumatoïde

Not yet recruiting
3
178
Europe
Prednisone, Cachet, Injection, OLUMIANT 4mg, IMRALDI 40mg, Prednisone
CHU de Bordeaux, Ministère de la Santé
rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), Body processes [G] - Immune system processes [G12]
 
 
ACTT-4, NCT04640168: Adaptive COVID-19 Treatment Trial 4

Hourglass Jul 2021 - Jul 2021 : Data from ACTT-4 trial in combination with Olumiant for treatment of COVID-19
Completed
3
1010
Japan, US, RoW
Baricitinib, Dexamethasone, Placebo, Remdesivir
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
05/21
06/21
2020-005081-34: A randomized study to evaluate the efficacy and Safety of Baricitinib to induce Remission and to spare Glucocorticoids in subjects with new-onset Polymyalgia Rheumatica. Eine randomisierte Studie zur Beurteilung der Wirksamkeit und Sicherheit von Baricitinib zur Remissionsinduktion und als Glukokortikoid sparender Wirkstoff in Patienten mit früher Polymyalgia rheumatica

Ongoing
3
18
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Medical University of Vienna, Medical University of Vienna
Polymyalgia rheumatica (PMR), Polymyalgia rheumatica (PMR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
BRAVE II, NCT03616964 / 2017-005027-25: A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-)

Hourglass Oct 2021 - Dec 2021 : From BRAVE II trials for SLE
Completed
3
778
Europe, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Systemic Lupus Erythematosus
09/21
10/21
2021-001338-21: A Study of Baricitinib in Children With COVID-19 (COV-BARRIER-PEDS)

Ongoing
3
24
Europe
Olumiant, LY3009104, Oral suspension
Eli Lilly and Company, Eli Lilly and Company
COVID-19 infection, COVID-19 infection, Diseases [C] - Virus Diseases [C02]
 
 
BAREBONE, NCT03701789: Effect of Baricitinib Treatment on Peripheral Bone in RA

Active, not recruiting
3
15
Europe
Baricitinib, Oliumiant
University of Erlangen-Nürnberg Medical School
Rheumatoid Arthritis, Bone Density, Finger Joints
10/21
10/21
BREEZE-AD6, NCT03559270: A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Hourglass Jan 2019 - Dec 2019 : Data from BREEZE-AD6 trial
Terminated
3
374
Canada, US
Baricitinib, LY3009104
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
10/21
06/22
BRAVE I, NCT03616912 / 2017-005026-37: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Hourglass Oct 2021 - Oct 2021 : From BRAVE I trial for SLE
Terminated
3
830
Europe, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Systemic Lupus Erythematosus
11/21
03/22
NCT04890626: Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

Completed
3
356
Europe
Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA], Baricitinib + dexamethasone, Dexamethasone
Instituto de Investigación Hospital Universitario La Paz
SARS-CoV-2 Infection
07/23
07/23
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Withdrawn
3
382
RoW
Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
COVID-19 Pneumonia
12/21
12/21
JUVE-BASIS, NCT03773978 / 2017-004518-24: A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Completed
3
220
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Juvenile Idiopathic Arthritis
01/22
01/22
AMMURAVID, NCT04832880 / 2020-001854-23: Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the Trial)

Not yet recruiting
3
4000
Europe
Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone
ASST Fatebenefratelli Sacco, AIFA
Covid19
03/22
12/22
SLE-BRAVE-X, NCT03843125 / 2017-005028-11: A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Hourglass Jul 2021 - Dec 2021 : Data from SLE-BRAVE-X trial for SLE
Terminated
3
1147
Europe, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Systemic Lupus Erythematosus
04/22
04/22
NCT05056558: Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Not yet recruiting
3
480
RoW
Baricitinib, Baricent, Placebo, Given Orally
Incepta Pharmaceuticals Ltd
Covid19
04/22
09/22
BREEZE-AD-PEDS, NCT03952559 / 2018-000349-38: A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Active, not recruiting
3
516
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
04/22
05/26
2022-000366-18: Efficacy and Tolerance of Baricitinib, a JAK inhibitor, in the treatment of refractory non-infectious uveitis Efficacité et Tolérance du Baricitinib, un inhibiteur de JAK, dans le traitement des uvéites non-infectieuses non-antérieures réfractaires

Not yet recruiting
3
33
Europe
Tablet, OLUMIANT
CHU de ROUEN, CHU de Rouen
Active non-anterior non-infectious uveitis, Active non-anterior non-infectious uveitis, Diseases [C] - Eye Diseases [C11]
 
 
NCT04088409 / 2019-000119-10: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active, not recruiting
3
30
Europe
Baricitinib, LY3009104, Adalimumab
Eli Lilly and Company
Uveitis
07/23
07/28
JAKUVEITE, NCT05651880: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Not yet recruiting
3
33
NA
Baricitinib 4 MG
University Hospital, Rouen
Active Non-anterior Non-infectious Uveitis
08/23
08/26
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
REVERSE-LC, NCT05858515: REVERSE-Long COVID-19 with Baricitinib Study

Withdrawn
3
550
US
Baricitinib 4 MG, Olumiant, Placebo
Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University
Post-Acute COVID-19 Syndrome
12/27
12/29
COV-BARRIER, NCT05074420 / 2021-001338-21: A Study of Baricitinib (LY3009104) in Children With COVID-19

Recruiting
3
24
Europe, US, RoW
Baricitinib, LY3009104
Eli Lilly and Company, Eli Lilly and Company
Covid19, Corona Virus Infection
12/24
12/24
REVERSE-LC, NCT06631287: Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Recruiting
3
550
US
Baricitinib, OLUMIANT, Placebo
Wes Ely, National Institutes of Health (NIH), National Institute on Aging (NIA)
Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
11/26
07/27
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, adalimumab, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/25
12/25
TREAT-HAP, NCT05914584: "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Not yet recruiting
3
450
Europe
Baricitinib 4 MG
Nantes University Hospital
Hospital-acquired Pneumonia
08/25
12/25
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BIRD, NCT04972760: Baricitinib in Patients With Relapsing or naïve Dermatomyositis

Recruiting
3
62
Europe
Baricitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Dermatomyositis
02/26
02/26
PALETTE, NCT06381661: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial

Not yet recruiting
3
2000
NA
Tocilizumab, Baricitinib, Anakinra, Hydrocortisone, Hydrocortisone and fludrocortisone, Heparin, Low molecular weight heparin, Recombinant humanThrombomodulin( rhTM), Sivelestat, Fresh frozen plasma, Usual care
Assistance Publique - Hôpitaux de Paris
Sepsis
05/29
04/32
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
09/26
12/28
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
NCT04358614: Baricitinib Therapy in COVID-19

Completed
2/3
12
Europe
Baricitinib 4 MG Oral Tablet, Lopinavir/Ritonavir tablets 250 mg/bid
Fabrizio Cantini
COVID, Pneumonia
04/20
04/20
BARI-COVID, NCT04320277: Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

Hourglass Jun 2020 - Jun 2020 : From BARI-COVID trial for patients with COVID-19
Unknown status
2/3
200
Europe
Baricitinib, Lopinavir/Ritonavir tablets 250 mg/bid
Hospital of Prato
Pharmacological Action
06/20
07/20
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Active, not recruiting
2/3
824
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
NCT04340232: Safety and Efficacy of Baricitinib for COVID-19

Withdrawn
2/3
0
US
Baricitinib
University of Colorado, Denver
COVID-19
08/21
10/21
NCT04517253: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Active, not recruiting
2/3
8
Japan
Baricitinib, LY3009104
Eli Lilly and Company
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
10/21
11/24
NCT04891133 / 2021-000541-41 / ACTRN12619000823178: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Terminated
2/3
290
Europe, RoW
Baricitinib, Olumiant, Placebo
Oslo University Hospital, Institut National de la Santé Et de la Recherche Médicale, France, Epidemiological and Clinical Research Information Network
Stroke, Memory deficits
12/22
01/23
NCT05686746: Use of Baricitenib to Maintain of Remission

Recruiting
2/3
80
RoW
Baricitinib 4 MG, Baricitinib 2 MG, MMF
Assiut University
Lupus or SLE, Nephritis
06/23
08/23
NCT06475820: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Active, not recruiting
2/3
150
RoW
Baricitinib, Vedolizumab, Abatacept, Cyclophosphamide
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
07/24
04/27

Download Options